Can fezolinetant tablets be purchased in the country?

As of October 2025, Fezolinetant has not been officially launched in mainland China. It is currently only approved for use in the United States, Japan and some European countries. The original drug is produced by Eisai Company of Japan. The overseas trade name is VEOZAH. The common specification is 45mg*30 tablets. It is used to treat menopausal vasomotor symptoms orally once a day. Domestic patients are temporarily unable to purchase the drug directly through hospital or pharmacy channels.

However, with the relaxation of international drug customs clearance and cross-border drug purchase policies, some patients can obtain the original version of Fezolinetant through overseas medical institutions or formal cross-border pharmacy channels Overseas selling prices vary by region, with a box usually costing around a few hundred dollars. In addition to the original drug, pharmaceutical companies such as Lucius of Laos have launched a generic version of Fezolinetant. Its active ingredients are the same as the original drug, and its efficacy and safety are similar, but the price is relatively more affordable.

Since this drug is a new type of non-hormonal menopausal drug, it still needs to go through the approval process of the National Food and Drug Administration (NMPA) before it can be officially sold in China. Industry experts predict that Fezolinetant is expected to be launched in China in the next few years to meet the huge treatment needs of menopausal women. At present, domestic doctors mostly use hormone replacement therapy (HRT) or phytoestrogen drugs to relieve hot flashes, and the introduction of Fezolinetant will become an important non-hormonal alternative.

If patients are interested in knowing how to use the drug, they should avoid purchasing the drug through informal channels. They can consult a qualified international drug purchase agency or participate in cross-border medical services. At the same time, your health status should be evaluated by a professional doctor before use to confirm whether it is suitable for this type of drug treatment.

In short, as an innovativeNK3 receptor antagonist, fizonatant has not yet been launched in China, but its safe and non-hormonal properties have attracted widespread attention around the world. As the approval process progresses, it is expected to become a new choice for domestic menopause management in the future.

Reference materials:https://www.veozah.com/

xa0